Enclomiphene

Enclomiphene selectively blocks estrogen receptors (primarily ER-alpha) in the hypothalamus and pituitary gland. By antagonizing estradiol at these sites, it removes the negative feedback signal that suppresses GnRH release. The hypothalamus responds with increased GnRH pulsatility, which stimulates the anterior pituitary to secrete more LH and FSH. LH drives Leydig cell testosterone production, while FSH supports Sertoli cell function and spermatogenesis. Unlike zuclomiphene (the cis-isomer in Clomid), enclomiphene has no estrogenic agonist activity, so it does not accumulate or cause paradoxical estrogenic effects.

Rapidly absorbed with high oral bioavailability. Peak plasma concentration in 1-3 hours. Half-life of approximately 10-12 hours — significantly shorter than zuclomiphene's 30-day half-life. This means no problematic accumulation during PCT. Metabolized hepatically. Reaches steady state within 2-3 days at consistent dosing. Clears the system within 2-3 days of discontinuation.

• ✓Stimulates natural testosterone production without the mood side effects of Clomid
• ✓No zuclomiphene accumulation — cleaner side effect profile
• ✓Preserves fertility by maintaining FSH and spermatogenesis
• ✓Short half-life allows for rapid dose adjustment and quick clearance if sides occur
• ✓Can be used as a long-term TRT alternative while maintaining testicular function
• ✓Effective PCT compound that restores HPTA function reliably
• ✓Better tolerated than both Clomid and Nolvadex for most users
• ✓Does not reduce IGF-1 as significantly as Nolvadex

• ⚠Headache (mild, usually transient)
• ⚠Hot flashes (less common than with Clomid)
• ⚠Mild nausea at higher doses
• ⚠Acne as testosterone rebounds
• ⚠Slightly elevated estradiol (proportional to testosterone increase — normal physiology)
• ⚠Rare: visual disturbances (much less common than with Clomid)
• ⚠Emotional sensitivity (mild compared to Clomid)

Contraindications

• 🚫Hypersensitivity to clomiphene or enclomiphene
• 🚫Pre-existing vision disorders
• 🚫Severe hepatic impairment
• 🚫Estrogen-dependent tumors
• 🚫Users who did not tolerate clomiphene (though many who cannot tolerate Clomid do fine on enclomiphene)

Standard PCT: Start 2 weeks after last long-ester injection or 3 days after short-ester. Run 25mg/day for 4-6 weeks. After 19-nors: HCG bridge 1000-1500 IU EOD for 2 weeks, then enclomiphene 25-50mg/day for 4-6 weeks. After mild cycles (Anavar-only, low-dose test): 12.5-25mg/day for 4 weeks may be sufficient. Long-term protocol (TRT alternative): 12.5-25mg/day ongoing with quarterly bloodwork monitoring. Confirm recovery with bloodwork 4 weeks post-cessation.

• 1.Enclomiphene is rapidly replacing Clomid as the go-to PCT SERM among informed users — if you have access, there is little reason to use regular Clomid
• 2.The short half-life is a major advantage: if you experience any side effects, they resolve within 2-3 days of stopping
• 3.Many users report being able to maintain near-TRT testosterone levels on 12.5-25mg/day long-term while preserving fertility — something exogenous testosterone cannot do
• 4.Pair with HCG pre-PCT for optimal results after suppressive cycles
• 5.No need to taper — you can simply stop after your PCT duration and natural production should sustain
• 6.Morning dosing is preferred by most users as it aligns with the natural diurnal testosterone rhythm
• 7.Start with 25mg and only increase to 50mg if bloodwork shows inadequate LH/FSH response after 2 weeks

1. [1]Wiehle RD et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia. J Endocrinol Invest. 2014;37(4):351-356.
2. [2]Kim ED et al. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men. BJU Int. 2016;118(4):634-640.
3. [3]Fontenot GK et al. A randomized study of enclomiphene citrate and testosterone gel for treatment of hypogonadism. Endocrine Practice. 2014.